Orgovyx (Relugolix)

Relugolix, the active ingredient in Orgovyx, is a selective GnRH antagonist presented as an oral tablet for oral use. It reduces circulating testosterone and is indicated for the treatment of advanced prostate cancer in men. The medication is formulated for once‑daily administration and is part of modern hormonal therapy strategies for oncology patients.

GNH USA supplies Orgovyx as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Orgovyx is a GnRH antagonist used in the management of advanced prostate cancer. It works by suppressing testosterone production, which fuels tumor growth.

- Advanced prostate cancer: provides testosterone suppression to control disease progression. - Metastatic castration‑sensitive prostate cancer: used in combination with androgen‑deprivation therapy to improve overall survival. - Hormone‑sensitive prostate cancer: helps achieve rapid and sustained castration levels of testosterone.

Orgovyx may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Hot flashes: transient episodes of warmth and sweating. - Decreased libido: reduced sexual desire. - Fatigue: general feeling of tiredness. - Headache: mild to moderate head pain. - Nausea: occasional upset stomach. - Musculoskeletal pain: aches in muscles or joints.

Serious or Rare Side Effects: - Cardiovascular events: myocardial infarction, stroke, or hypertension. - Liver enzyme elevations: increased ALT/AST levels. - Adrenal insufficiency: signs of cortisol deficiency. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Bone density loss: increased risk of fractures with prolonged use.

When prescribing Orgovyx, clinicians should consider several safety aspects.

- Cardiovascular risk: assess history of heart disease before initiating therapy. - Liver function: monitor hepatic enzymes regularly during treatment. - Bone health: evaluate bone mineral density, especially in long‑term use. - Drug interactions: review concomitant medications that affect CYP3A4. - Pregnancy and breastfeeding: not indicated for women; avoid use during pregnancy. - Storage: Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Orgovyx may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly reduce relugolix exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase relugolix levels and risk of toxicity.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor INR as hormonal changes can affect clotting. - Antihypertensives: blood pressure may fluctuate; adjust dosing as needed. - Other hormonal agents: concurrent use may alter endocrine balance. - Statins metabolized by CYP3A4: observe for increased statin concentrations.